- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Andrew J. Armstrong, MD, ScM, FACP | Authors
In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not Yet
October 15, 2014
Meta-analyses of patients with low-volume metastatic hormone-sensitive prostate cancer will likely be required to attain sufficient power to address the role of docetaxel in this setting.